ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer

Mendeley Data 2026 Dataset Open access

Read full text
Authors: Frida Rantanen, Alice Dini, Harlan R. Barker, Franziska Bentz, Lassi Paavolainen, Daniela Ungureanu
DOI: 10.17632/dd6bvtrv9b
Cited by: 0

Abstract

We developed long-term resistant pre-clinical models to two complementary drugs: adavosertib (ADA) and paclitaxel (PTX). Through multiomics functional profiling we identified distinct transcriptomic and morphological changes in the ovarian cancer resistant models. - seurat_counts.csv.gz: raw counts for sc-data - seurat_metadata.csv.gz: metadata for sc-data - CellPainting_raw_data.zip: Cell Painting features extracted with CellProfiler - SourceData_FigureS3.zip: Source data for figure S3 - SourceData_FigureS4.zip: Source data for figure S4 - SourceData_FigureS6.zip: Source data for figure S6

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PI3K/AKT/mTOR signaling in cancer PARP inhibition in cancer therapy

Publication details

Journal / source
Mendeley Data
Publication date
14 January 2026
Document type
Dataset